HEARTLINE HSM Genoa Cardiology Meeting - Aristea

Conclusioni
Sulla base degli studi RE-LY, ROCKET AF ed ARISTOTLE i nuovi anticoagulanti orali dabigatran,
rivaroxaban ed apixaban hanno dimostrato un’ efcacia sostanzialmente sovrapponibile
a quella del warfarin nella prevenzione del rischio tromboembolico nei pazienti affetti
da FA, associata ad un migliore prolo di sicurezza, soprattutto per quanto riguarda la signicativa
riduzione delle emorragie intracraniche, che rappresentano la complicanza più
temibile della TAO. Presentano inoltre il vantaggio della non necessità di un monitoraggio
periodico dell’anticoagulazione e della scarsa interferenza con concomitanti terapie (1 ) .
E’ auspicabile che dopo l’immissione in commercio dei nuovi anticoagulanti orali i risultati
favorevoli dei trial vengano confermati anche nella pratica clinica quotidiana, eventualmente
con una verica attraverso la realizzazione di registri prospettici osservazionali.
Bibliograa
1. Schirmer SH, Baumhäkel M, Neuberger HR et al. Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation. Current clinical
evidence and future developments. J Am Coll Cardiol 2010; 6:2067-76
2. Olsson SB, for the Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin
inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial brillation (SPORTIF III): randomised controlled
trial. Lancet 200 ; 62:1691-98
. Albers GW, Diener HC, Frison L, et al. for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients
with nonvalvular atrial brillation: a randomized trial. JAMA 200 ;29 :690-98
. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial brillation. N Engl J Med
2009; 61(12):11 9- 1
. Connolly SJ, Ezekowitz MD, Yusuf S et al.; Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly
identied events in the RE-LY trial. N Engl J Med 2010; 6 (19):187 -6 (Letter)
6. Olsson SB, Rasmussen LH, Tveit A et al. Safety and tolerability of an immediate-release formulation of theoral direct thrombin
inhibitor AZD08 7 in the prevention of stroke and systemic embolism in patients with atrial brillation. Thromb Haemost
2010;10 ( ):60 -12
7. Amadeus Investigators, Bousser MG, Bouthier J, Büller HR et al. Comparison of idraparinux with vitamin K antagonists for
prevention of thromboembolism in patients with atrial brillation: a randomised, open-label, non-inferiority trial. Lancet
2008; 71: 1 -21
8. Patel MR, Mahaffey KW, Garg J, et al. for the ROCKET AF Investigators. Rivaroxaban versus Warfarin in Nonvalvular Atrial
Fibrillation. N Engl J Med 2011; 6 : 88 -891
9. Connolly SJ, Eikelboom J, Joyner C, et al for the AVERROES Steering Committee and Investigators. Apixaban in Patients with
Atrial Fibrillation. N Engl J Med 2011; 6 :806-17
10.Granger CB, Alexander JH, McMurray JJV, et al for the ARISTOTLE Committees and Investigators. Apixaban versus Warfarin in
Patients with Atrial Fibrillation. N Engl J Med 2011; 68: 981-992
11.Ruff CT, Giugliano RP, Antman EM et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients
with atrial brillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-
Thrombolysis In Myocardial Infarction study 8 (ENGAGE AF-TIMI 8). Am Heart J 2010;160( ):6 - 1
12.Di Pasquale G, Riva L. Prolassi cardioembolica 2011: siamo vicini al tramonto del warfarin? G Ital Cardiol 2011;12(9): 6-6
1 .Mega JL. A new era for anticoagulation in atrial brillation. N Engl J Med 2011; 6 :10 2- (Editorial).
121